Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 211 Results May 5, 2026 Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates April 2, 2026 Minerva Announces Leadership Transition March 31, 2026 Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia March 25, 2026 Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026 March 12, 2026 Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum March 11, 2026 Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates March 4, 2026 Minerva Neurosciences to Participate in The Citizens Life Sciences Conference January 26, 2026 Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 November 19, 2025 Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors November 5, 2025 Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates 12345...1020...»